Navigation Links
Trapping prostate cancer cells to keep them from spreading provides hope
Date:3/10/2011

Tampa, Fla. (March 10, 2011) When prostate cancer stem cells (CSCs) were enclosed in self-assembling nanomaterials made of peptides (SAP), the SAP stopped cancer stem cell colony formation and also stopped the division of cancer cells in laboratory cultures (in vitro). According to the international team of researchers who built and tested the nano-sized traps and published their results in a recent issue of Cell Transplantation (20:1), which is freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ , the cancer cells grew and multiplied after they were "liberated" from their SAP prisons.

In their article, the researchers suggested that CSCs may be the origin of prostate tumor metastasis, making them an "ideal target" for inhibiting disease metastasis. The group's previous work in building nanomaterials showed that by using SAPs they were able to control the proliferation, elongation and maturation of cells in vitro.

"In this study, we have shown that prostate CSCs can be placed into stasis for an extended period of time without causing them to differentiate," said study corresponding author Dr. Rutledge Ellis-Behnke of the Heidelberg University-based Nanomedicine Translational Think Tank. "If cells are prevented from migrating away from the treatment, they could be subjected to additional targeting."

For the researchers, the isolation of cancer cells with stem-like characteristics "provides solid evidence" that CSCs may exist within the tumor. Additionally, CSCs may account for some treatment failures when treatments are unable to successfully target cancer stem cells, which may be resistant to chemotherapy drugs. Too, CSCs have been found to be more invasive than non-CSCs. The authors speculated that by injecting the material directly into the tumor, it may be possible to stop the spread of metastatic cells.

The research team also suggested that trapping CSCs in the nanomaterial would allow for loading of the SAP with chemotherapy agents, thus offering an increased effectiveness of a localized treatment when targeted cancer cells were unable to 'escape' their chemical enemies. This approach for treating metastatic hormone refractory prostate cancer (HRPC) - a cancer for which all current therapies fail - may offer hope as a successful treatment.

"The goal of cancer therapy is to reduce the ability of cancer cells to divide and migrate," said Dr. Ellis-Behnke. "Accordingly, we have shown that SAP can completely inhibit a prostate CSC from self-renewal while preserving its viability and stem cell properties."

Their study concluded that SAP may be "an effective nanomaterial for inhibiting cancer progression and metastasis."

"The ability to sequester cancer stem cells in SAP to prevent the spread of a prostate cancer is a big step toward finding effective treatments for cancer," Shinn-Zong Lin, professor of neurosurgery at China University Medical Hospital, Taiwan and chair of the Pan Pacific Symposium on Stem Cell Research where this work was first presented. "It will be of considerable interest to se how this technology develops."


'/>"/>

Contact: David Eve
celltransplantation@gmail.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related medicine news :

1. New twist on potential malaria drug target acts by trapping parasites in cells
2. Rapid Rise in PSA Levels a Poor Predictor of Prostate Cancer: Study
3. Newer Drug May Help Prevent Fracture in Men With Prostate Cancer
4. PSA velocity screening for prostate cancer may lead to unnecessary biopsies
5. Change in PSA level does not predict prostate cancer
6. PSA Screening for Prostate Cancer Dips in Large U.S. Health Network
7. HJF signs distribution agreement for antibody to evaluate prostate cancer
8. PSA Test Cut-off Could Signal Low-Risk Prostate Cancer
9. Research presented at 2011 GU Cancers Symposium highlights advances in treatment of prostate cancer
10. Could Hair Loss at 20 Signal Higher Prostate Cancer Risk?
11. Losing hair at 20 is linked to increased risk of prostate cancer in later life
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , ... March 27, 2017 , ... ... for clear braces. People who want straight teeth without the extensive time commitment ... in Clearwater, FL, without acquiring a referral. A custom-designed series of virtually invisible ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... for custom smile makeovers without requiring a referral. Trimble Dental offers ... disease treatment, cosmetic dentistry and dental implants. Whether patients have discolored, crooked or ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who want to ... missing teeth can now have them placed by Dr. Manju Kejriwal, with or without ... Beam technology to increase the accuracy of each dental implant placement. The i-CAT CBCT ...
(Date:3/27/2017)... ... ... Drs. Justin Kolnick, Kara Diamond, Randall Barton, Keith Hope and Bilal Chaudhry ... this treatment plays in protecting oral health, along with the benefits of receiving ... a root canal in White Plains, NY or their second location in Mt. Kisco, ...
(Date:3/27/2017)... ... March 27, 2017 , ... Biotechnology and ... and engagement over the household brands of Top-20 pharma by optimizing clinical trial ... partnering with the right outsourcing payments provider can provide the technology, infrastructure, and ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Summary This report provides all the information ... and activities since 2010. Description The Partnering Deals and ... partnering activity of one of the world,s leading life sciences ... purchase to ensure inclusion of the most up to date ... delivered in PDF format within 1 working day of receipt ...
(Date:3/27/2017)... , March 27, 2017 ... better understand Eli Lilly and its partnering interests and activities ... 2010 report provides an in-depth insight into the partnering activity ... On demand company reports are prepared upon purchase to ... company data. The report will be delivered in ...
(Date:3/27/2017)... , March 27, 2017 ... specialty clinical-stage pharmaceutical company specializing in the development of ... public offering in the United States ... each ADS representing 40 ordinary shares of the ... In addition, Therapix has granted the underwriters a ...
Breaking Medicine Technology: